<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiotomsk</journal-id><journal-title-group><journal-title xml:lang="ru">Сибирский журнал клинической и экспериментальной медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Siberian Journal of Clinical and Experimental Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2713-2927</issn><issn pub-type="epub">2713-265X</issn><publisher><publisher-name>TSU publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29001/2073-8552-2022-37-4-63-69</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiotomsk-1621</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Особенности течения COVID-19 у пациентов с хронической обструктивной болезнью легких, бронхиальной астмой и сопутствующими сердечно-сосудистыми заболеваниями</article-title><trans-title-group xml:lang="en"><trans-title>Features of COVID-19 in patients with chronic obstructive pulmonary disease, bronchial asthma, and cardiovascular comorbidity</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8477-8551</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самойлов</surname><given-names>К. B.</given-names></name><name name-style="western" xml:lang="en"><surname>Samoylov</surname><given-names>K. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Самойлов Кирилл Владимирович, студент VI курса</p><p>634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Kirill V. Samoylov, 6th Year Student</p><p>2, Moskovsky tract, Tomsk, 634055</p></bio><email xlink:type="simple">samoilov.krl@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7699-5492</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Букреева</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Bukreeva</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Букреева Екатерина Борисовна, доктор медицинских наук, профессор, профессор кафедры пропедевтики внутренних болезней с курсом терапии педиатрического факультета</p><p>634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Ekaterina B. Bukreeva, Dr. Sci. (Med.), Professor, Department of Propaedeutics of Internal Diseases with a Course of Therapy</p><p>2, Moskovsky tract, Tomsk, 634055</p></bio><email xlink:type="simple">kbukreeva@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5700-1640</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боярко</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyarko</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Боярко Валентина Владимировна, кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней с курсом терапии педиатрического факультета</p><p>634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Valentina V. Boyarko, Cand. Sci. (Med.), Associate Professor, Department of Propaedeutics of Internal Diseases with a Course of Therapy</p><p>2, Moskovsky tract, Tomsk, 634055</p></bio><email xlink:type="simple">vvboyarko@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7226-0328</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Геренг</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gereng</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Геренг Елена Андреевна, доктор медицинских наук, доцент, профессор кафедры морфологии и общей патологии</p><p>634050, Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>Elena A. Gereng, Dr. Sci. (Med.), Associate Professor, Professor of the Department of Morphology and General Pathology</p><p>2, Moskovsky tract, Tomsk, 634055</p><p> </p></bio><email xlink:type="simple">e-gereng@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет Министерства здравоохранения Российской Федерации; &#13;
Городская клиническая больница № 3 имени Б.И. Альперовича</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University; &#13;
City Clinical Hospital No. 3 named after B.I. Alperovich</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>17</day><month>01</month><year>2023</year></pub-date><volume>37</volume><issue>4</issue><fpage>63</fpage><lpage>69</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Самойлов К.B., Букреева Е.Б., Боярко В.В., Геренг Е.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Самойлов К.B., Букреева Е.Б., Боярко В.В., Геренг Е.А.</copyright-holder><copyright-holder xml:lang="en">Samoylov K.V., Bukreeva E.B., Boyarko V.V., Gereng E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.sibjcem.ru/jour/article/view/1621">https://www.sibjcem.ru/jour/article/view/1621</self-uri><abstract><sec><title>Цель работы</title><p>Цель работы: выявить особенности течения Covid-19 у пациентов, страдающих хронической обструктивной болезнью легких (ХОБЛ), бронхиальной астмой (БА) и сердечно-сосудистыми заболеваниями (ССЗ).</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В ретроспективное исследование отобраны 58 пациентов с новой коронавирусной инфекцией, которые были разделены на 3 группы: 1-я группа – 12 пациентов с ХОБЛ/ССЗ; 2-я группа – 15 пациентов с БА/ССЗ; 3-я группа – 31 пациент только с ССЗ. Всем больным проводилось общеклиническое обследование, общее и биохимическое исследования крови, коагулограмма, мультиспиральная компьютерная томография (МСКТ), определялся уровень сывороточного ферритина.</p></sec><sec><title>Результаты</title><p>Результаты. Выраженность одышки была больше у больных с ХОБЛ/ССЗ по сравнению с пациентами с БА/ССЗ и пациентами без бронхолегочной патологии. Частота десатурации была наименьшей в группе БА/ССЗ по сравнению с группой ХОБЛ/ССЗ. Более низкий уровень сатурации наблюдался в группе ХОБЛ/ССЗ относительно БА/ССЗ. Степень поражения легочной ткани также преобладала в группе ХОБЛ/ССЗ по сравнению с больными без бронхолегочной патологии. Больные только с ССЗ продемонстрировали наименьший уровень лейкоцитов по сравнению со всеми исследуемыми группами. Однако уровень тромбоцитов преобладал в группе ССЗ по сравнению с группой с ХОБЛ/ССЗ. Сывороточный ферритин у больных с ХОБЛ/ССЗ был выше, чем в группе БА/ССЗ.</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с ХОБЛ наблюдалось более тяжелое течение коронавирусной инфекции за счет выраженности одышки, низких показателей сатурации, высоких значений ферритина, а также большей выраженности поражения легких по данным компьютерной томографии. У больных БА имело место менее тяжелое течение коронавирусной инфекции, что проявлялось меньшей выраженностью одышки, высокими показателями сатурации, редкими эпизодами десатурации и низкими значениями ферритина.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. The aim of the study was to identify the features of a new coronavirus infection in patients with chronic obstructive pulmonary disease (COPD), bronchial asthma (BA), and cardiovascular disease (CVD).</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. The retrospective study included 58 patients with novel coronavirus infection, which were divided into four groups: group 1 comprised 12 patients with COPD and CVD; group 2 comprised 15 patients with BA and CVD; and group 3 comprised 31 patients with CVD only. All patients underwent a clinical examination, complete blood count, biochemical blood examination, coagulation testing, serum ferritin test, and multi-slice computed tomography.</p></sec><sec><title>Results</title><p>Results. The severity of dyspnea was greater in patients with COPD/CVD compared with BA/CVD, and in patients without bronchopulmonary pathology. The frequency of desaturation was the lowest in BA/CVD group compared with COPD/CVD and COPD/BA/CVD. A lower level of saturation was observed in COPD/CVD group in comparison with BA/CVD. The extent of lung damage also prevailed in group with COPD/CVD compared with patients without bronchopulmonary pathology. Patients with CVD only demonstrated the lowest level of leukocytes in contrast with all other study groups. However, the platelet count prevailed in the CVD group compared with the COPD/CVD group. Serum ferritin in patients with COPD/CVD was higher than in the AD/CVD group.</p></sec><sec><title>Conclusion</title><p>Conclusion. Patients with COPD had more severe coronavirus infection due to severity of dyspnea, low saturation indicators, high values of ferritin, and greater severity of lung damage according to computed tomography. Patients with asthma were prone to a less severe course of coronavirus infection due to less dyspnea, rare episodes of desaturation, high saturation rates, and low ferritin values.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>хроническая обструктивная болезнь легких</kwd><kwd>бронхиальная астма</kwd><kwd>сердечно-сосудистые заболевания</kwd><kwd>SARS-CoV-2</kwd><kwd>новая короновирусная инфекция.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>chronic obstructive pulmonary disease</kwd><kwd>bronchial asthma</kwd><kwd>cardiovascular disease</kwd><kwd>SARS-CoV-2</kwd><kwd>new coronavirus infection</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Beyerstedt S., Casaro E.B., Rangel É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905–919. DOI: 10.1007/s10096-020-04138-6.</mixed-citation><mixed-citation xml:lang="en">Beyerstedt S., Casaro E.B., Rangel É.B. COVID-19: Angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARSCoV-2 infection. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40(5):905–919. DOI: 10.1007/s10096-020-04138-6.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Brüggen M.C. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564– 1581. DOI: 10.1111/all.14364.</mixed-citation><mixed-citation xml:lang="en">Azkur A.K., Akdis M., Azkur D., Sokolowska M., van de Veen W., Brüggen M.C. et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564– 1581. DOI: 10.1111/all.14364.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am. J. Respir. Crit. Care Med. 2020;201(11):1380–1388. DOI: 10.1164/rccm.202002-0445OC.</mixed-citation><mixed-citation xml:lang="en">Feng Y., Ling Y., Bai T., Xie Y., Huang J., Li J. et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. Am. J. Respir. Crit. Care Med. 2020;201(11):1380–1388. DOI: 10.1164/rccm.202002-0445OC.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kalyanaraman Marcello R., Dolle J., Grami S., Adule R., Li Z., Tatem K. et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One. 2020;15(12):e0243027. DOI: 10.1371/journal.pone.0243027.</mixed-citation><mixed-citation xml:lang="en">Kalyanaraman Marcello R., Dolle J., Grami S., Adule R., Li Z., Tatem K. et al. Characteristics and outcomes of COVID-19 patients in New York City’s public hospital system. PLoS One. 2020;15(12):e0243027. DOI: 10.1371/journal.pone.0243027.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Guan W.J., Ni Z.Y., Hu Y., Yu Q., Liu W., Pu J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.</mixed-citation><mixed-citation xml:lang="en">Guan W.J., Ni Z.Y., Hu Y., Yu Q., Liu W., Pu J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720. DOI: 10.1056/NEJMoa2002032.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gerayeli F.V., Milne S., Cheung C., Li X., Yang C.W.T., Tam A. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. DOI: 10.1016/j.eclinm.2021.100789.</mixed-citation><mixed-citation xml:lang="en">Gerayeli F.V., Milne S., Cheung C., Li X., Yang C.W.T., Tam A. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021;33:100789. DOI: 10.1016/j.eclinm.2021.100789.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wu F., Zhou Y., Wang Z., Xie M., Shi Z., Tang Z. et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811–1823. DOI: 10.21037/jtd-20-1914.</mixed-citation><mixed-citation xml:lang="en">Wu F., Zhou Y., Wang Z., Xie M., Shi Z., Tang Z. et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: A multicenter, retrospective, observational study. J. Thorac. Dis. 2020;12(5):1811–1823. DOI: 10.21037/jtd-20-1914.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. DOI: 10.1001/jama.2020.6775.</mixed-citation><mixed-citation xml:lang="en">Richardson S., Hirsch J.S., Narasimhan M., Crawford J.M., McGinn T., Davidson K.W. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. DOI: 10.1001/ jama.2020.6775.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin. Immunol. 2020;146(2):307–314.e4. DOI: 10.1016/j.jaci.2020.06.010.</mixed-citation><mixed-citation xml:lang="en">Chhiba K.D., Patel G.B., Vu T.H.T., Chen M.M., Guo A., Kudlaty E. et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin. Immunol. 2020;146(2):307–314.e4. DOI: 10.1016/j.jaci.2020.06.010.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu S., Cao Y., Du T., Zhi Y. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. J. Allergy Clin. Immunol. Pract. 2021;9(2):693–701. DOI: 10.1016/j.jaip.2020.11.054.</mixed-citation><mixed-citation xml:lang="en">Liu S., Cao Y., Du T., Zhi Y. Prevalence of Comorbid Asthma and Related Outcomes in COVID-19: A Systematic Review and Meta-Analysis. J. Allergy Clin. Immunol. Pract. 2021;9(2):693–701. DOI: 10.1016/j.jaip.2020.11.054.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Luo J., Chen Y.L., Chen W., Duncan D.A., Hussain H., Sohail B. et al. Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy Asthma Clin. Immunol. 2021;17(1):67. DOI: 10.1186/s13223-021-00569-8.</mixed-citation><mixed-citation xml:lang="en">Luo J., Chen Y.L., Chen W., Duncan D.A., Hussain H., Sohail B. et al. Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19. Allergy Asthma Clin. Immunol. 2021;17(1):67. DOI: 10.1186/s13223-021-00569-8.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Beurnier A., Jutant E.M., Jevnikar M., Boucly A., Pichon J., Preda M. et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur. Respir. J. 2020;56(5):2001875. DOI: 10.1183/13993003.01875-2020.</mixed-citation><mixed-citation xml:lang="en">Beurnier A., Jutant E.M., Jevnikar M., Boucly A., Pichon J., Preda M. et al. Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. Eur. Respir. J. 2020;56(5):2001875. DOI: 10.1183/13993003.01875-2020.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. DOI: 10.1016/j.ijid.2020.03.017.</mixed-citation><mixed-citation xml:lang="en">Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 2020;94:91–95. DOI: 10.1016/j.ijid.2020.03.017.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.</mixed-citation><mixed-citation xml:lang="en">Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. DOI: 10.1016/S0140-6736(20)30566-3.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Müllerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: Systematic literature review. Chest. 2013;144(4):1163– 1178. DOI: 10.1378/chest.12-2847.</mixed-citation><mixed-citation xml:lang="en">Müllerova H., Agusti A., Erqou S., Mapel D.W. Cardiovascular comorbidity in COPD: Systematic literature review. Chest. 2013;144(4):1163–1178. DOI: 10.1378/chest.12-2847.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Lee H.M., Truong S.T., Wong N.D. Association of adult-onset asthma with specific cardiovascular conditions. Respir. Med. 2012;106(7):948– 953. DOI: 10.1016/j.rmed.2012.02.017.</mixed-citation><mixed-citation xml:lang="en">Lee H.M., Truong S.T., Wong N.D. Association of adult-onset asthma with specific cardiovascular conditions. Respir. Med. 2012;106(7):948– 953. DOI: 10.1016/j.rmed.2012.02.017.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Matsushita K., Ding N., Kou M., Hu X., Zhang L., Huo P. et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob. Heart. 2020;15(1):64. DOI: 10.5334/gh.814.</mixed-citation><mixed-citation xml:lang="en">Matsushita K., Ding N., Kou M., Hu X., Zhang L., Huo P. et al. The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis. Glob. Heart. 2020;15(1):64. DOI: 10.5334/gh.814.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Jacobs M., Van Eeckhoutte H.P., Wijnant S.R.A., Janssens W., Joos G.F., Brusselle G.G. et al. Increased expression of ACE2, the SARSCoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur. Respir. J. 2020;56(2):2002378. DOI: 10.1183/13993003.02378-2020.</mixed-citation><mixed-citation xml:lang="en">Jacobs M., Van Eeckhoutte H.P., Wijnant S.R.A., Janssens W., Joos G.F., Brusselle G.G. et al. Increased expression of ACE2, the SARSCoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects. Eur. Respir. J. 2020;56(2):2002378. DOI: 10.1183/13993003.02378-2020.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am. J. Respir. Crit. Care Med. 2020;202(1):83–90. DOI: 10.1164/rccm.202003-0821OC.</mixed-citation><mixed-citation xml:lang="en">Peters M.C., Sajuthi S., Deford P., Christenson S., Rios C.L., Montgomery M.T. et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am. J. Respir. Crit. Care Med. 2020;202(1):83–90. DOI: 10.1164/rccm.202003-0821OC.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Dahan S., Segal G., Katz I., Hellou T., Tietel M., Bryk G. et al. Ferritin as a marker of severity in COVID-19 patients: A fatal correlation. Isr. Med. Assoc. J. 2020;22(8):494–500.</mixed-citation><mixed-citation xml:lang="en">Dahan S., Segal G., Katz I., Hellou T., Tietel M., Bryk G. et al. Ferritin as a marker of severity in COVID-19 patients: A fatal correlation. Isr. Med. Assoc. J. 2020;22(8):494–500.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
